Changes in the treatment landscape of metastatic hormone‐sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study
International Journal of Urology · 2024-11 · 31 (11) · 1248-1255
DOI: 10.1111/iju.15546 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Urology, online erschienen am 19.07.2024. Verfasst von Fumihiko Urabe und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Androgen Receptor Antagonists. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Background
A multicenter database was utilized to examine the current treatment landscape and clinical outcomes among patients with metastatic hormone‐sensitive prostate cancer (mHSPC) following approval of upfront androgen receptor signaling inhibitors (ARSIs).
Methods
We retrospectively analyzed patients with mHSPC who commenced treatment between February 2018 and June 2023. The Kaplan–Meier method was used to assess oncological outcomes, including time to castration‐resistant prostate cancer (CRPC), progression‐free survival 2 (PFS2, duration from initial treatment to tumor progression during second‐line treatment), cancer‐specific survival (CSS), and overall survival (OS). Cox regression analyses were performed to determine the impact of treatment choices on oncological outcomes. In addition, the incidence rate of adverse events was assessed.
Results
In total, 829 patients were analyzed; 42.5% received ARSIs with androgen deprivation therapy (ADT), 44.0% received combined androgen blockade (CAB), and 13.5% received ADT alone. Kaplan–Meier curves and multivariate Cox regression analyses indicated higher rates of CRPC and shorter PFS2 in patients treated with CAB versus ARSIs with ADT. By contrast, CSS and OS were not significantly different between the ARSI with ADT group and the CAB group. Grades 3–4 adverse events occurred in 1.9% of patients receiving CAB and 6.0% of those receiving ARSIs with ADT.
Conclusions
Initial treatment with ARSIs in combination with ADT resulted in a longer time to CRPC and longer PFS2 compared to CAB. Although CAB and ADT alone were associated with fewer adverse events, ARSIs with ADT should be considered a first‐line treatment option given its superior oncological outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
- Department of Urology, Jikei Katsushika Medical Center, Tokyo, Japan.
- Department of Urology, Jikei Kashiwa Hospital, Chiba, Japan.
ORCID-Profile: Fumihiko Urabe, Takafumi Yanagisawa, Wataru Fukuokaya, Keiichiro Mori, Keiichiro Miyajima, Yu Imai, Shunsuke Tsuzuki, Jun Miki, Takahiro Kimura
Zitieren
APA
Urabe, F., Muramoto, K., Yanagisawa, T., Fukuokaya, W., Mori, K., Tashiro, K., Katsumi, K., Takahashi, H., Yoshihara, K., Miyajima, K., Imai, Y., Iwatani, K., Kayano, S., Igarashi, T., Murakami, M., Tsuzuki, S., Shimomura, T., Yamada, H., Miki, J., …, & JIKEI‐YAYOI Collaborative Group (2024). Changes in the treatment landscape of metastatic hormone‐sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study. International Journal of Urology, 31(11), 1248-1255. https://doi.org/10.1111/iju.15546
Vancouver
Urabe F, Muramoto K, Yanagisawa T, Fukuokaya W, Mori K, Tashiro K, et al. Changes in the treatment landscape of metastatic hormone‐sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study. International Journal of Urology. 2024;31(11):1248-1255. doi:10.1111/iju.15546
BibTeX
@article{Urabe2024,
author = {Urabe, Fumihiko and Muramoto, Katsuki and Yanagisawa, Takafumi and Fukuokaya, Wataru and Mori, Keiichiro and Tashiro, Kojiro and Katsumi, Kota and Takahashi, Hidetsugu and Yoshihara, Kentaro and Miyajima, Keiichiro and Imai, Yu and Iwatani, Kosuke and Kayano, Sotaro and Igarashi, Taro and Murakami, Masaya and Tsuzuki, Shunsuke and Shimomura, Tatsuya and Yamada, Hiroki and Miki, Jun and Kimura, Takahiro and JIKEI‐YAYOI Collaborative Group, JIKEI‐YAYOI Collaborative Group},
title = {Changes in the treatment landscape of metastatic hormone‐sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study},
journal = {International Journal of Urology},
year = {2024},
volume = {31},
number = {11},
pages = {1248--1255},
doi = {10.1111/iju.15546}
}
EUVIMED